PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1

Peritonitis is still a major cause of the death in peritoneal dialysis (PD) patients despite the significant decline of the peritonitis rates in recent years. The present study is designed to evaluate the therapeutic potential of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biosci Rep
Hlavní autoři: Zhang, Yunfang, Feng, Junxia, Wang, Qi, Zhao, Shili, Xu, Jiaqi, Li, Hongyan
Médium: Artigo
Jazyk:Inglês
Vydáno: Portland Press Ltd. 2018
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6013694/
https://ncbi.nlm.nih.gov/pubmed/29871973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20180009
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky